Tarsier Pharma is a late-clinical-stage company dedicated to the development and commercialization of a breakthrough therapeutic approach for better and safer treatment of autoimmune inflammatory ocular diseases. The TRS Platform Technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases. It is currently being developed as both eye drops and intravitreal injections. TRS has the potential to effectively control a range of autoimmune and inflammatory ocular diseases as potently as steroids but without the negative side effects. The company's investors include a wholly owned subsidiary company of Sun Pharmaceutical Industries Limited, BioLight Life Sciences Ltd, as well as private investors and family offices. The company has also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 879598.